Lauren Meyer, PharmD, MSPBA Candidate

Biosimilars present a cost-saving opportunity for the health care system, but significant challenges inhibit uptake in the US market.

Specialty pharmacy stakeholders must strike a delicate balance between cost concerns and health outcomes, while keeping the patient at the center.

With the growth of specialty medications and the high-touch care that is needed to ensure optimal outcomes, a niche market focused on providing ancillary services for these drugs has grown in popularity.

A high-touch patient care model with enhanced data collection may help stop the ongoing opioid problem.